Show simple item record

dc.contributor.authorMiddleton, G
dc.contributor.authorSilcocks, P
dc.contributor.authorCox, T
dc.contributor.authorValle, Juan W
dc.contributor.authorWadsley, J
dc.contributor.authorPropper, D
dc.contributor.authorCoxon, F
dc.contributor.authorRoss, P
dc.contributor.authorMadhusudan, S
dc.contributor.authorRoques, T
dc.contributor.authorCunningham, D
dc.contributor.authorFalk, S
dc.contributor.authorWadd, N
dc.contributor.authorHarrison, M
dc.contributor.authorCorrie, Pippa
dc.contributor.authorIveson, Tim
dc.contributor.authorRobinson, A
dc.contributor.authorMcAdam, K
dc.contributor.authorEatock, M
dc.contributor.authorEvans, J
dc.contributor.authorArcher, C
dc.contributor.authorHickish, T
dc.contributor.authorGarcia-Alonso, A
dc.contributor.authorNicolson, M
dc.contributor.authorSteward, W
dc.contributor.authorAnthoney, A
dc.contributor.authorGreenhalf, W
dc.contributor.authorShaw, V
dc.contributor.authorCostello, E
dc.contributor.authorNaisbitt, D
dc.contributor.authorRawcliffe, C
dc.contributor.authorNanson, G
dc.contributor.authorNeoptolemos, J
dc.date.accessioned2014-07-08T14:15:11Z
dc.date.available2014-07-08T14:15:11Z
dc.date.issued2014-07
dc.identifier.citationGemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. 2014, 15 (8):829-40 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid24954781
dc.identifier.doi10.1016/S1470-2045(14)70236-0
dc.identifier.urihttp://hdl.handle.net/10541/322604
dc.description.abstractWe aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer.
dc.language.isoenen
dc.rightsArchived with thanks to The lancet oncologyen
dc.titleGemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentUniversity of Birmingham, Edgbaston, Birmingham, UK.en
dc.identifier.journalThe Lancet Oncologyen
refterms.dateFOA2020-05-01T15:07:50Z
html.description.abstractWe aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer.


Files in this item

Thumbnail
Name:
TeloVac Lancet Oncology Revised ...
Size:
617.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record